JP2016515536A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515536A5 JP2016515536A5 JP2016503448A JP2016503448A JP2016515536A5 JP 2016515536 A5 JP2016515536 A5 JP 2016515536A5 JP 2016503448 A JP2016503448 A JP 2016503448A JP 2016503448 A JP2016503448 A JP 2016503448A JP 2016515536 A5 JP2016515536 A5 JP 2016515536A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- substituted
- unsubstituted
- ethoxycarbonylamino
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000002947 alkylene group Chemical group 0.000 claims 6
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- -1 R C is —F Chemical group 0.000 claims 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000002993 cycloalkylene group Chemical group 0.000 claims 3
- FMNGLFKMWOZMJZ-MZNJEOGPSA-N (2r)-3-(4-bromophenyl)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]benzoyl]amino]propanoic acid Chemical compound C([C@@H](NC(=O)C1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=C(Br)C=C1 FMNGLFKMWOZMJZ-MZNJEOGPSA-N 0.000 claims 2
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 2
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 2
- 150000000022 5-membered heteroarenes Chemical class 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- DNTASSMVWDKGEL-KBMIEXCESA-N (2r)-2-[[4-[3-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]methylamino]-3-[4-(trifluoromethyl)phenyl]propanoic acid Chemical compound C([C@@H](NCC1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C=CC=CC=1)C(O)=O)C1=CC=C(C(F)(F)F)C=C1 DNTASSMVWDKGEL-KBMIEXCESA-N 0.000 claims 1
- DVQWHRUNKRFWKU-CJFMBICVSA-N (2r)-2-[[4-[3-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]methylamino]-3-phenylpropanoic acid Chemical compound C([C@@H](NCC1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 DVQWHRUNKRFWKU-CJFMBICVSA-N 0.000 claims 1
- ITTQHEXJRGBDRV-MZNJEOGPSA-N (2r)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]benzoyl]amino]-3-(2-fluorophenyl)propanoic acid Chemical compound C([C@@H](NC(=O)C1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=CC=C1F ITTQHEXJRGBDRV-MZNJEOGPSA-N 0.000 claims 1
- SQFCAGDNKYIPQF-VOIUYBSRSA-N (2r)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]benzoyl]amino]-3-(3,4-difluorophenyl)propanoic acid Chemical compound C([C@@H](NC(=O)C1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=C(F)C(F)=C1 SQFCAGDNKYIPQF-VOIUYBSRSA-N 0.000 claims 1
- BIWJMEMDKAXHNL-MZNJEOGPSA-N (2r)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]benzoyl]amino]-3-(4-fluorophenyl)propanoic acid Chemical compound C([C@@H](NC(=O)C1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=C(F)C=C1 BIWJMEMDKAXHNL-MZNJEOGPSA-N 0.000 claims 1
- FVGWGHOSJIRUFY-KBMIEXCESA-N (2r)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]benzoyl]amino]-3-(4-methylphenyl)propanoic acid Chemical compound C([C@@H](NC(=O)C1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=C(C)C=C1 FVGWGHOSJIRUFY-KBMIEXCESA-N 0.000 claims 1
- JEACLEXWCNRNKN-HOYKHHGWSA-N (2r)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]benzoyl]amino]-3-phenylpropanoic acid Chemical compound C([C@@H](NC(=O)C1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=CC=C1 JEACLEXWCNRNKN-HOYKHHGWSA-N 0.000 claims 1
- XCLWZCYDJNBLCW-IQGLISFBSA-N (2r)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]phenyl]methylamino]-3-[4-(trifluoromethyl)phenyl]propanoic acid Chemical compound C([C@@H](NCC1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=C(C(F)(F)F)C=C1 XCLWZCYDJNBLCW-IQGLISFBSA-N 0.000 claims 1
- FXGHIICVGOZMMB-OPAMFIHVSA-N (2r)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]phenyl]methylamino]-3-cyclopropylpropanoic acid Chemical compound C([C@@H](NCC1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1CC1 FXGHIICVGOZMMB-OPAMFIHVSA-N 0.000 claims 1
- WBYQMFJYFSEDBU-KBMIEXCESA-N (2r)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]phenyl]methylamino]-3-phenylpropanoic acid Chemical compound C([C@@H](NCC1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=CC=C1 WBYQMFJYFSEDBU-KBMIEXCESA-N 0.000 claims 1
- ARXHIRFXSXLYHD-KBMIEXCESA-N (2r)-3-(2-chlorophenyl)-2-[[4-[3-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]methylamino]propanoic acid Chemical compound C([C@@H](NCC1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1Cl ARXHIRFXSXLYHD-KBMIEXCESA-N 0.000 claims 1
- ZAJATRVMUICHSW-MZNJEOGPSA-N (2r)-3-(2-chlorophenyl)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]benzoyl]amino]propanoic acid Chemical compound C([C@@H](NC(=O)C1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=CC=C1Cl ZAJATRVMUICHSW-MZNJEOGPSA-N 0.000 claims 1
- XPFZMUSJNQAECK-IQGLISFBSA-N (2r)-3-(2-chlorophenyl)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]phenyl]methylamino]propanoic acid Chemical compound C([C@@H](NCC1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=CC=C1Cl XPFZMUSJNQAECK-IQGLISFBSA-N 0.000 claims 1
- IMIXACYBJVVYOY-KBMIEXCESA-N (2r)-3-(2-fluorophenyl)-2-[[4-[3-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]methylamino]propanoic acid Chemical compound C([C@@H](NCC1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1F IMIXACYBJVVYOY-KBMIEXCESA-N 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- BYOMTTIAEXZFDJ-MRXNPFEDSA-N 1-[4-[4-[5-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-4-fluoropyrazol-1-yl]phenyl]-2-fluorophenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(F)C=NN1C(C=C1)=CC=C1C(C=C1F)=CC=C1C1(C(O)=O)CC1 BYOMTTIAEXZFDJ-MRXNPFEDSA-N 0.000 claims 1
- XVNWTGXJZLFDKA-MRXNPFEDSA-N 1-[4-[4-[5-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-4-fluoropyrazol-1-yl]phenyl]-3-fluorophenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(F)C=NN1C(C=C1)=CC=C1C(C(=C1)F)=CC=C1C1(C(O)=O)CC1 XVNWTGXJZLFDKA-MRXNPFEDSA-N 0.000 claims 1
- LGXDKSKWIVKEQA-GOSISDBHSA-N 1-[4-[4-[5-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-4-fluoropyrazol-1-yl]phenyl]-3-methylphenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(F)C=NN1C(C=C1)=CC=C1C(C(=C1)C)=CC=C1C1(C(O)=O)CC1 LGXDKSKWIVKEQA-GOSISDBHSA-N 0.000 claims 1
- KGBNHXHOPVUASI-QGZVFWFLSA-N 1-[4-[4-[5-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-4-fluoropyrazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(F)C=NN1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 KGBNHXHOPVUASI-QGZVFWFLSA-N 0.000 claims 1
- NXDMYFBKUGPDMK-GOSISDBHSA-N 1-[4-[4-[5-[[(1r)-1-phenylethoxy]carbonylamino]-4-(trifluoromethyl)pyrazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C=CC=CC=1)C(=O)NC1=C(C(F)(F)F)C=NN1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 NXDMYFBKUGPDMK-GOSISDBHSA-N 0.000 claims 1
- ZMBYEYYGLMMXFD-VGOKPJQXSA-N 2-[[4-[3-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]methoxy]-3-phenylpropanoic acid Chemical compound O([C@H](C)C=1C=CC=CC=1)C(=O)NC=1C(C)=NOC=1C(C=C1)=CC=C1COC(C(O)=O)CC1=CC=CC=C1 ZMBYEYYGLMMXFD-VGOKPJQXSA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- BBDSWHRPUYCMKX-PLEWWHCXSA-N 3-cyclopropyl-2-[[4-[3-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]methoxy]propanoic acid Chemical compound O([C@H](C)C=1C=CC=CC=1)C(=O)NC=1C(C)=NOC=1C(C=C1)=CC=C1COC(C(O)=O)CC1CC1 BBDSWHRPUYCMKX-PLEWWHCXSA-N 0.000 claims 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801426P | 2013-03-15 | 2013-03-15 | |
| US201361801231P | 2013-03-15 | 2013-03-15 | |
| US61/801,231 | 2013-03-15 | ||
| US61/801,426 | 2013-03-15 | ||
| US201361827409P | 2013-05-24 | 2013-05-24 | |
| US61/827,409 | 2013-05-24 | ||
| PCT/US2014/030712 WO2014145873A2 (en) | 2013-03-15 | 2014-03-17 | Heterocyclic compounds useful in the treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019020553A Division JP6843903B2 (ja) | 2013-03-15 | 2019-02-07 | 疾患の治療に有用な複素環化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515536A JP2016515536A (ja) | 2016-05-30 |
| JP2016515536A5 true JP2016515536A5 (cg-RX-API-DMAC7.html) | 2017-04-20 |
| JP6482086B2 JP6482086B2 (ja) | 2019-03-13 |
Family
ID=51538557
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503448A Active JP6482086B2 (ja) | 2013-03-15 | 2014-03-17 | 疾患の治療に有用な複素環化合物 |
| JP2019020553A Active JP6843903B2 (ja) | 2013-03-15 | 2019-02-07 | 疾患の治療に有用な複素環化合物 |
| JP2024059851A Active JP7754979B2 (ja) | 2013-03-15 | 2024-04-03 | 疾患の治療に有用な複素環化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019020553A Active JP6843903B2 (ja) | 2013-03-15 | 2019-02-07 | 疾患の治療に有用な複素環化合物 |
| JP2024059851A Active JP7754979B2 (ja) | 2013-03-15 | 2024-04-03 | 疾患の治療に有用な複素環化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10000459B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2988743B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6482086B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102090231B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN105142635B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2014232383B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112015023267B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2906931C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2988743T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA033923B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2855173T3 (cg-RX-API-DMAC7.html) |
| MX (3) | MX382748B (cg-RX-API-DMAC7.html) |
| PT (1) | PT2988743T (cg-RX-API-DMAC7.html) |
| SG (3) | SG11201507459YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014145873A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019246109A1 (en) | 2018-06-18 | 2019-12-26 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| EA033923B1 (ru) * | 2013-03-15 | 2019-12-10 | Эпиджен Байосайенсиз, Инк. | Гетероциклические соединения, применимые в лечении заболеваний |
| KR20180082564A (ko) * | 2015-11-20 | 2018-07-18 | 우베 고산 가부시키가이샤 | Nash의 치료 또는 예방을 위한 의약 조성물 |
| KR102292989B1 (ko) * | 2017-03-29 | 2021-08-26 | 재단법인 아산사회복지재단 | S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물 |
| JP7202383B2 (ja) * | 2017-12-19 | 2023-01-11 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸 |
| US11312706B2 (en) | 2017-12-19 | 2022-04-26 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as LPA antagonists |
| WO2019126086A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as lpa antagonists |
| WO2019126099A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| JP7301839B2 (ja) | 2017-12-19 | 2023-07-03 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのピラゾールｎ－連結のカルバモイルシクロヘキシル酸 |
| US11352345B2 (en) | 2017-12-19 | 2022-06-07 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azoles as LPA antagonists |
| SMT202100716T1 (it) | 2017-12-19 | 2022-01-10 | Bristol Myers Squibb Co | Carbamoil cicloesil acidi triazolo-m-collegati come antagonisti di lpa |
| ES2925626T3 (es) | 2017-12-19 | 2022-10-19 | Bristol Myers Squibb Co | Acidos isoxazol-O-carbamoilciclohexílicos como antagonistas de LPA |
| US11261180B2 (en) | 2017-12-19 | 2022-03-01 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as LPA antagonists |
| CN113366000A (zh) | 2018-09-18 | 2021-09-07 | 百时美施贵宝公司 | 作为lpa拮抗剂的氧杂双环酸 |
| JP7427658B2 (ja) | 2018-09-18 | 2024-02-05 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロペンチル酸 |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| US20240122934A1 (en) * | 2019-10-16 | 2024-04-18 | University Of South Florida | Compositions and methods of treatment for inhibiting capillary tube regression |
| JP7431961B2 (ja) | 2019-11-15 | 2024-02-15 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニストとしてのトリアゾールカルバメートピリジルスルホンアミド及びその使用 |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| AU2021282986B2 (en) | 2020-06-03 | 2024-03-07 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| WO2021252917A2 (en) | 2020-06-11 | 2021-12-16 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2022006470A1 (en) | 2020-07-01 | 2022-01-06 | Vanderbilt University | Methods of treatment for a kidney disease |
| WO2022013378A1 (en) * | 2020-07-16 | 2022-01-20 | Chiesi Farmaceutici S.P.A. | Amido cyclohexane acid derivatives as lpa receptor inhibitors |
| CA3191452A1 (en) * | 2020-08-11 | 2022-02-17 | Viva Star Biosciences Limited | Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as lpa receptor antagonists |
| TWI818538B (zh) | 2021-05-11 | 2023-10-11 | 美商基利科學股份有限公司 | Ｌｐａ受體拮抗劑及其用途 |
| WO2022241023A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| EP4444707A1 (en) | 2021-12-08 | 2024-10-16 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| AR128613A1 (es) | 2022-02-25 | 2024-05-29 | Lhotse Bio Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa |
| EP4622713A1 (en) * | 2022-11-24 | 2025-10-01 | Lhotse Bio, Inc. | Compounds and compositions for treating conditions associated with lpa receptor activity |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2308B1 (en) | 1999-05-31 | 2005-09-12 | اف. هوفمان- لاروش أيه جي | Derivatives of phenylpyrmidine |
| ATE420878T1 (de) | 2000-02-18 | 2009-01-15 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
| ATE447970T1 (de) | 2001-02-08 | 2009-11-15 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
| CA2487315A1 (en) | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
| CA2528929A1 (en) | 2003-06-11 | 2004-12-23 | Sankyo Company Limited | Cyclic tertiary amine compound |
| JP4692281B2 (ja) | 2003-08-05 | 2011-06-01 | 味の素株式会社 | 新規アゾール化合物 |
| CA2543882A1 (en) | 2003-10-30 | 2005-05-19 | Merck & Co., Inc. | Aralkyl amines as cannabinoid receptor modulators |
| EP1732892B1 (en) | 2004-03-26 | 2008-09-17 | F.Hoffmann-La Roche Ag | Tetrahydrocarbazoles and derivatives |
| WO2005099688A2 (en) | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| AU2006261845C1 (en) | 2005-06-27 | 2013-05-16 | Exelixis Patent Company Llc | Imidazole based LXR modulators |
| TW200803740A (en) * | 2005-12-16 | 2008-01-16 | Du Pont | 5-aryl isoxazolines for controlling invertebrate pests |
| EP2096111A1 (en) | 2006-11-20 | 2009-09-02 | Japan Tobacco Inc. | Pyrazoles and use thereof as drugs |
| EP2202226B1 (en) | 2007-10-18 | 2013-06-05 | Kumiai Chemical Industry CO., LTD. | 3-alkoxy-1-phenylpyrazole derivative and pest control agent |
| CN102083827A (zh) | 2008-07-07 | 2011-06-01 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的噻唑烷化合物 |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| IN2012DN00754A (cg-RX-API-DMAC7.html) * | 2009-08-04 | 2015-06-19 | Amira Pharmaceuticals Inc | |
| JP4683154B2 (ja) | 2009-08-12 | 2011-05-11 | 横浜ゴム株式会社 | 冷媒移送用ホース |
| GB2474120B (en) * | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| WO2011159635A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions |
| US20130253019A1 (en) | 2010-06-15 | 2013-09-26 | John Howard Hutchinson | Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye |
| WO2011159633A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| US20120031985A1 (en) | 2010-08-09 | 2012-02-09 | Terry Lien Do | Fault tolerant appliance |
| EP2648726B1 (en) | 2010-12-07 | 2018-04-04 | Amira Pharmaceuticals, Inc. | Polycyclic lpa1 antagonist and uses thereof |
| CA2820817A1 (en) * | 2010-12-07 | 2012-06-14 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists and uses thereof |
| US8785442B2 (en) | 2011-01-30 | 2014-07-22 | Curegenix, Inc. | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof |
| WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| WO2013025733A1 (en) * | 2011-08-15 | 2013-02-21 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| WO2013085824A1 (en) | 2011-12-04 | 2013-06-13 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
| NZ630124A (en) | 2012-03-20 | 2016-01-29 | Seragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| CN104411692A (zh) | 2012-06-20 | 2015-03-11 | 霍夫曼-拉罗奇有限公司 | 作为lpar拮抗剂的n-烷基三唑化合物 |
| EA201492281A1 (ru) | 2012-06-20 | 2015-04-30 | Ф. Хоффманн-Ля Рош Аг | Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) |
| UA109867C2 (ru) | 2012-06-20 | 2015-10-12 | Ф. Хоффманн-Ля Рош Аг | Замещенные соединения пиразола как антагонисты рецепторов лизофосфатидной кислоты (lpar) |
| RU2649398C2 (ru) | 2012-12-28 | 2018-04-03 | Убе Индастриз, Лтд. | Галогензамещенное гетероциклическое соединение |
| WO2014113485A1 (en) | 2013-01-15 | 2014-07-24 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| WO2019246109A1 (en) | 2018-06-18 | 2019-12-26 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| EA033923B1 (ru) | 2013-03-15 | 2019-12-10 | Эпиджен Байосайенсиз, Инк. | Гетероциклические соединения, применимые в лечении заболеваний |
| WO2015066456A1 (en) | 2013-10-31 | 2015-05-07 | Bristol-Myers Squibb Company | Radioligands for imaging the lpa-1 receptor |
| KR102433588B1 (ko) | 2014-06-27 | 2022-08-19 | 우베 가부시키가이샤 | 할로겐 치환 헤테로환 화합물의 염 |
-
2014
- 2014-03-17 EA EA201591607A patent/EA033923B1/ru unknown
- 2014-03-17 DK DK14762555.2T patent/DK2988743T3/da active
- 2014-03-17 WO PCT/US2014/030712 patent/WO2014145873A2/en not_active Ceased
- 2014-03-17 US US14/776,954 patent/US10000459B2/en active Active
- 2014-03-17 EP EP14762555.2A patent/EP2988743B1/en active Active
- 2014-03-17 ES ES14762555T patent/ES2855173T3/es active Active
- 2014-03-17 JP JP2016503448A patent/JP6482086B2/ja active Active
- 2014-03-17 KR KR1020157028061A patent/KR102090231B1/ko active Active
- 2014-03-17 AU AU2014232383A patent/AU2014232383B2/en active Active
- 2014-03-17 CA CA2906931A patent/CA2906931C/en active Active
- 2014-03-17 MX MX2015013303A patent/MX382748B/es unknown
- 2014-03-17 CN CN201480015333.XA patent/CN105142635B/zh active Active
- 2014-03-17 SG SG11201507459YA patent/SG11201507459YA/en unknown
- 2014-03-17 SG SG10201803833WA patent/SG10201803833WA/en unknown
- 2014-03-17 PT PT147625552T patent/PT2988743T/pt unknown
- 2014-03-17 BR BR112015023267-1A patent/BR112015023267B1/pt active IP Right Grant
-
2018
- 2018-06-05 US US16/000,283 patent/US10570103B2/en active Active
- 2018-06-18 US US16/010,755 patent/US10526298B2/en active Active
-
2019
- 2019-02-07 JP JP2019020553A patent/JP6843903B2/ja active Active
- 2019-04-17 AU AU2019202731A patent/AU2019202731B2/en active Active
- 2019-06-18 AU AU2019288275A patent/AU2019288275B2/en active Active
- 2019-06-18 MX MX2020014300A patent/MX2020014300A/es unknown
- 2019-06-18 BR BR112020025927-6A patent/BR112020025927A2/pt unknown
- 2019-06-18 CN CN201980047732.7A patent/CN112424174B/zh active Active
- 2019-06-18 CN CN202410150847.1A patent/CN118290357A/zh active Pending
- 2019-06-18 US US18/015,289 patent/US20230286928A1/en active Pending
- 2019-06-18 SG SG11202012656WA patent/SG11202012656WA/en unknown
-
2020
- 2020-02-07 US US16/784,486 patent/US11427552B2/en active Active
- 2020-12-18 MX MX2024011839A patent/MX2024011839A/es unknown
-
2024
- 2024-04-03 JP JP2024059851A patent/JP7754979B2/ja active Active